Why the study?
Does standard cardiac therapy improve left ventricular dysfunction in a patient with late-onset doxorubicin-induced congestive heart failure?
Does standard cardiac therapy improve left ventricular dysfunction in a patient with late-onset doxorubicin-induced congestive heart failure?
Answers are grounded in this paper and cite their sources.
This case report demonstrates that late-onset doxorubicin-induced cardiomyopathy can be reversible and responsive to standard cardiac therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
M. Cohen (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: